Warning letter
Patient First Corporation: warning letter of Mar 15, 2005
FDA warning letter UCM075319 · Baltimore District Office
Key facts
| Reference number | UCM075319 |
|---|---|
| Company | Patient First Corporation |
| Subject | Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated |
| Issue date | Mar 15, 2005 |
| Posted date | Mar 15, 2005 |
| Issuing office | Baltimore District Office |
| Product type | Drugs |
| CFR sections cited | 211, 211.42(c), 211.42(d), 211.46(c), 211.67(b), 211.166(a) |
| Country | 3 |
| Inspection city | Glen Allen |
| Inspection ZIP | 23060-9263 |
| Inspection start date | Nov 23, 2004 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: